Skip to content

Study · Observational study · 2026

11 results

Semaglutide Versus Dulaglutide and Liraglutide in Chinese Patients With T2DM: A Multicenter Real-World Study.

Xie Z, Gan B, Cao W, Liu J, Chen J

Obesity (Silver Spring, Md.)20 Nov 2025Cited by 3 (Europe PMC)

PMID41266832 (opens in a new tab)DOI10.1002/oby.70065 (opens in a new tab)PepBankPUB-41266832
Publisher pagePubMedAsk about this study
Jump to 11 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study11

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanObservational studyEfficacy outcome

    After propensity matching in Chinese adults with type 2 diabetes, semaglutide was associated with greater HbA1c reduction than dulaglutide.

    In plain wordsIn matched Chinese adults with type 2 diabetes, semaglutide was linked to greater HbA1c reduction than dulaglutide.

    Peptide
    Semaglutide
    Outcome
    DecreaseHbA1c reduction
    Study

    n: not reported in source

    Comparator
    Dulaglutide
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    1.0 mgAs given in this study (human).

    Measurements

    HbA1c reduction
    −0.27%
    versus dulaglutide

    Source sentences

    Summary
    After 1:1 propensity score matching, semaglutide demonstrated significantly greater HbA1c reduction compared to both dulaglutide (-0.27% ± 0.70%, p = 0.008) and liraglutide (-0.39% ± 0.87%, p < 0.001), along with higher glycemic target achievement rates.
    2 context sentences
    Summary · context
    This multicenter, retrospective, real-world study enrolled Chinese adults with T2DM who initiated GLP-1 receptor agonist therapy in endocrinology clinics between January 1, 2022, and August 31, 2024.
    Summary · context
    This multicenter retrospective study included 111, 74, and 107 patients treated with semaglutide 1.0 mg, dulaglutide 1.5 mg, and liraglutide 1.8 mg, respectively.
  2. 02HumanObservational studyEfficacy outcome

    After propensity matching in Chinese adults with type 2 diabetes, semaglutide was associated with greater HbA1c reduction than liraglutide.

    In plain wordsIn matched Chinese adults with type 2 diabetes, semaglutide was linked to greater HbA1c reduction than liraglutide.

    Peptide
    Semaglutide
    Outcome
    DecreaseHbA1c reduction
    Study

    n: not reported in source

    Comparator
    Liraglutide
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    1.0 mgAs given in this study (human).

    Measurements

    HbA1c reduction
    −0.39%
    versus liraglutide

    Source sentences

    Summary
    After 1:1 propensity score matching, semaglutide demonstrated significantly greater HbA1c reduction compared to both dulaglutide (-0.27% ± 0.70%, p = 0.008) and liraglutide (-0.39% ± 0.87%, p < 0.001), along with higher glycemic target achievement rates.
    2 context sentences
    Summary · context
    This multicenter, retrospective, real-world study enrolled Chinese adults with T2DM who initiated GLP-1 receptor agonist therapy in endocrinology clinics between January 1, 2022, and August 31, 2024.
    Summary · context
    This multicenter retrospective study included 111, 74, and 107 patients treated with semaglutide 1.0 mg, dulaglutide 1.5 mg, and liraglutide 1.8 mg, respectively.
  3. 03HumanObservational studyEfficacy outcome

    After propensity matching in Chinese adults with type 2 diabetes, semaglutide was associated with higher glycemic target achievement than dulaglutide.

    In plain wordsIn matched Chinese adults with type 2 diabetes, semaglutide was linked to reaching glucose targets more often than dulaglutide.

    Peptide
    Semaglutide
    Outcome
    IncreaseGlycemic target achievement
    Study

    n: not reported in source

    Comparator
    Dulaglutide
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    1.0 mgAs given in this study (human).

    Source sentences

    Summary
    After 1:1 propensity score matching, semaglutide demonstrated significantly greater HbA1c reduction compared to both dulaglutide (-0.27% ± 0.70%, p = 0.008) and liraglutide (-0.39% ± 0.87%, p < 0.001), along with higher glycemic target achievement rates.
    2 context sentences
    Summary · context
    This multicenter, retrospective, real-world study enrolled Chinese adults with T2DM who initiated GLP-1 receptor agonist therapy in endocrinology clinics between January 1, 2022, and August 31, 2024.
    Summary · context
    This multicenter retrospective study included 111, 74, and 107 patients treated with semaglutide 1.0 mg, dulaglutide 1.5 mg, and liraglutide 1.8 mg, respectively.
  4. 04HumanObservational studyEfficacy outcome

    After propensity matching in Chinese adults with type 2 diabetes, semaglutide was associated with higher glycemic target achievement than liraglutide.

    In plain wordsIn matched Chinese adults with type 2 diabetes, semaglutide was linked to reaching glucose targets more often than liraglutide.

    Peptide
    Semaglutide
    Outcome
    IncreaseGlycemic target achievement
    Study

    n: not reported in source

    Comparator
    Liraglutide
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    1.0 mgAs given in this study (human).

    Source sentences

    Summary
    After 1:1 propensity score matching, semaglutide demonstrated significantly greater HbA1c reduction compared to both dulaglutide (-0.27% ± 0.70%, p = 0.008) and liraglutide (-0.39% ± 0.87%, p < 0.001), along with higher glycemic target achievement rates.
    2 context sentences
    Summary · context
    This multicenter, retrospective, real-world study enrolled Chinese adults with T2DM who initiated GLP-1 receptor agonist therapy in endocrinology clinics between January 1, 2022, and August 31, 2024.
    Summary · context
    This multicenter retrospective study included 111, 74, and 107 patients treated with semaglutide 1.0 mg, dulaglutide 1.5 mg, and liraglutide 1.8 mg, respectively.
  5. 05HumanObservational studyEfficacy outcome

    In matched Chinese adults with type 2 diabetes, liraglutide 1.8 mg had less HbA1c reduction than semaglutide.

    In plain wordsIn matched Chinese adults with type 2 diabetes, liraglutide was associated with less HbA1c lowering than semaglutide.

    Peptide
    Liraglutide
    Outcome
    DecreaseHbA1c reduction
    Study

    n: not reported in source

    Comparator
    Semaglutide
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    1.8 mgAs given in this study (human).

    Source sentences

    Summary
    After 1:1 propensity score matching, semaglutide demonstrated significantly greater HbA1c reduction compared to both dulaglutide (-0.27% ± 0.70%, p = 0.008) and liraglutide (-0.39% ± 0.87%, p < 0.001), along with higher glycemic target achievement rates.
    2 context sentences
    Summary · context
    This multicenter, retrospective, real-world study enrolled Chinese adults with T2DM who initiated GLP-1 receptor agonist therapy in endocrinology clinics between January 1, 2022, and August 31, 2024.
    Summary · context
    This multicenter retrospective study included 111, 74, and 107 patients treated with semaglutide 1.0 mg, dulaglutide 1.5 mg, and liraglutide 1.8 mg, respectively.
  6. 06HumanObservational studyEfficacy outcome

    In matched Chinese adults with type 2 diabetes, liraglutide 1.8 mg had lower glycemic target achievement than semaglutide.

    In plain wordsIn matched Chinese adults with type 2 diabetes, liraglutide was associated with reaching glycemic targets less often than semaglutide.

    Peptide
    Liraglutide
    Outcome
    DecreaseGlycemic target achievement
    Study

    n: not reported in source

    Comparator
    Semaglutide
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    1.8 mgAs given in this study (human).

    Source sentences

    Summary
    After 1:1 propensity score matching, semaglutide demonstrated significantly greater HbA1c reduction compared to both dulaglutide (-0.27% ± 0.70%, p = 0.008) and liraglutide (-0.39% ± 0.87%, p < 0.001), along with higher glycemic target achievement rates.
    2 context sentences
    Summary · context
    This multicenter, retrospective, real-world study enrolled Chinese adults with T2DM who initiated GLP-1 receptor agonist therapy in endocrinology clinics between January 1, 2022, and August 31, 2024.
    Summary · context
    This multicenter retrospective study included 111, 74, and 107 patients treated with semaglutide 1.0 mg, dulaglutide 1.5 mg, and liraglutide 1.8 mg, respectively.

Studies that did not test the peptide alone5

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

  1. 07HumanNot a test of Semaglutide aloneObservational studySafety outcome

    Among Chinese adults with type 2 diabetes, across semaglutide, dulaglutide, and liraglutide, no significant safety-profile differences were observed.

    In plain wordsAmong Chinese adults with type 2 diabetes, no significant safety-profile differences were observed across semaglutide, dulaglutide, and liraglutide.

    Peptide
    Semaglutide
    Outcome
    No significant changeSafety profile
    Study

    n: not reported in source

    Analysis
    Exploratory
    Outcome group
    Adverse events · Whole body

    Source sentences

    Summary
    No significant differences in safety profiles were observed among the three treatment groups.
    3 context sentences
    Summary · context
    We compared the effectiveness of these agents on HbA1c and weight loss, with safety as a key exploratory endpoint.
    Summary · context
    This multicenter, retrospective, real-world study enrolled Chinese adults with T2DM who initiated GLP-1 receptor agonist therapy in endocrinology clinics between January 1, 2022, and August 31, 2024.
    Summary · context
    This multicenter retrospective study included 111, 74, and 107 patients treated with semaglutide 1.0 mg, dulaglutide 1.5 mg, and liraglutide 1.8 mg, respectively.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  2. 08HumanNot a test of Liraglutide aloneObservational studySafety outcome

    Among Chinese adults with type 2 diabetes, across semaglutide, dulaglutide, and liraglutide, no significant safety-profile differences were observed.

    In plain wordsAmong Chinese adults with type 2 diabetes, no significant safety-profile differences were observed across semaglutide, dulaglutide, and liraglutide.

    Peptide
    Liraglutide
    Outcome
    No significant changeSafety profile
    Study

    n: not reported in source

    Analysis
    Exploratory
    Outcome group
    Adverse events · Whole body

    Source sentences

    Summary
    No significant differences in safety profiles were observed among the three treatment groups.
    3 context sentences
    Summary · context
    We compared the effectiveness of these agents on HbA1c and weight loss, with safety as a key exploratory endpoint.
    Summary · context
    This multicenter, retrospective, real-world study enrolled Chinese adults with T2DM who initiated GLP-1 receptor agonist therapy in endocrinology clinics between January 1, 2022, and August 31, 2024.
    Summary · context
    This multicenter retrospective study included 111, 74, and 107 patients treated with semaglutide 1.0 mg, dulaglutide 1.5 mg, and liraglutide 1.8 mg, respectively.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  3. 09Computer modelNot a test of Semaglutide aloneIn silicoEfficacy outcome

    For Chinese adults with type 2 diabetes, the UK Prospective Diabetes Study Outcomes Model 2.1 associated semaglutide with improved projected all-death outcomes.

    In plain wordsFor modelled Chinese type 2 diabetes care, semaglutide was associated with better projected all-death outcomes.

    Peptide
    Semaglutide
    Outcome
    Direction not reportedAll death endpoint
    Study

    n: not reported in source

    UK Prospective Diabetes Study Outcomes Model 2.1
    Outcome group
    Mortality · Whole body

    Source sentences

    Summary
    Semaglutide was associated with improved outcomes in all death, cardiovascular death, and other death endpoints.
    3 context sentences
    Summary · context
    Additionally, the UK Prospective Diabetes Study Outcomes Model 2.1 was utilized to project long-term health outcomes.
    Summary · context
    This multicenter, retrospective, real-world study enrolled Chinese adults with T2DM who initiated GLP-1 receptor agonist therapy in endocrinology clinics between January 1, 2022, and August 31, 2024.
    Summary · context
    This multicenter retrospective study included 111, 74, and 107 patients treated with semaglutide 1.0 mg, dulaglutide 1.5 mg, and liraglutide 1.8 mg, respectively.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  4. 10Computer modelNot a test of Semaglutide aloneIn silicoEfficacy outcome

    For Chinese adults with type 2 diabetes, the UK Prospective Diabetes Study Outcomes Model 2.1 associated semaglutide with improved projected cardiovascular-death outcomes.

    In plain wordsFor modelled Chinese type 2 diabetes care, semaglutide was associated with better projected cardiovascular-death outcomes.

    Peptide
    Semaglutide
    Outcome
    Direction not reportedCardiovascular death endpoint
    Study

    n: not reported in source

    UK Prospective Diabetes Study Outcomes Model 2.1
    Outcome group
    Mortality · Cardiovascular

    Source sentences

    Summary
    Semaglutide was associated with improved outcomes in all death, cardiovascular death, and other death endpoints.
    3 context sentences
    Summary · context
    Additionally, the UK Prospective Diabetes Study Outcomes Model 2.1 was utilized to project long-term health outcomes.
    Summary · context
    This multicenter, retrospective, real-world study enrolled Chinese adults with T2DM who initiated GLP-1 receptor agonist therapy in endocrinology clinics between January 1, 2022, and August 31, 2024.
    Summary · context
    This multicenter retrospective study included 111, 74, and 107 patients treated with semaglutide 1.0 mg, dulaglutide 1.5 mg, and liraglutide 1.8 mg, respectively.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  5. 11Computer modelNot a test of Semaglutide aloneIn silicoEfficacy outcome

    For Chinese adults with type 2 diabetes, the UK Prospective Diabetes Study Outcomes Model 2.1 associated semaglutide with improved projected other-death outcomes.

    In plain wordsFor modelled Chinese type 2 diabetes care, semaglutide was associated with better projected other-death outcomes.

    Peptide
    Semaglutide
    Outcome
    Direction not reportedOther death endpoint
    Study

    n: not reported in source

    UK Prospective Diabetes Study Outcomes Model 2.1
    Outcome group
    Mortality · Whole body

    Source sentences

    Summary
    Semaglutide was associated with improved outcomes in all death, cardiovascular death, and other death endpoints.
    3 context sentences
    Summary · context
    Additionally, the UK Prospective Diabetes Study Outcomes Model 2.1 was utilized to project long-term health outcomes.
    Summary · context
    This multicenter, retrospective, real-world study enrolled Chinese adults with T2DM who initiated GLP-1 receptor agonist therapy in endocrinology clinics between January 1, 2022, and August 31, 2024.
    Summary · context
    This multicenter retrospective study included 111, 74, and 107 patients treated with semaglutide 1.0 mg, dulaglutide 1.5 mg, and liraglutide 1.8 mg, respectively.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:06 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.